Scarica l'app Stockscreener
8.47
8.51%
0.70
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché RNAZ Giù?
Forum
Previsione
Frazionamento azionario
Transcode Therapeutics Inc Borsa (RNAZ) Ultime notizie
RNAZ | TransCode Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Avoiding Lag: Real-Time Signals in (RNAZ) Movement - Stock Traders Daily
TransCode Adjourns Annual Meeting Amid Nasdaq Listing Steps - TipRanks
Nasdaq review delays TransCode (NASDAQ: RNAZ) vote on preferred conversion - Stock Titan
TransCode Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNAZ) - TradingView
TransCode Therapeutics, Inc. Actuals & Estimates (BOATS:RNAZ) - TradingView
Transcode Therapeutics Inc (RNAZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RNAZ Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Transcode Therapeutics Inc (RNAZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Discipline and Rules-Based Execution in RNAZ Response - Stock Traders Daily
TransCode Highlights Progress of Lead RNA Cancer Therapeutic - TipRanks
Transcript : TransCode Therapeutics, Inc.Special Call - marketscreener.com
TransCode Therapeutics posts investor presentation detailing Phase 1a safety, Phase 2a plan and $12.8M cash - TradingView
TransCode Therapeutics (NASDAQ: RNAZ) furnishes new investor presentation via Form 8-K - Stock Titan
Transcode Therapeutics Inc (RNAZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Transcode Therapeutics Inc (RNAZ) Institutional Confidence - TradingKey
Transcode Therapeutics Inc (RNAZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Transcode Therapeutics Inc (RNAZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Transcode Therapeutics Inc (RNAZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Transcode Therapeutics Inc (RNAZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Transcode Therapeutics Inc (RNAZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TransCode Therapeutics (RNAZ) Rallies 3.27% as Biotech Stock Tests Key ResistanceFactor Crowding - newsline.com
RNAZ Technical Analysis & Stock Price Forecast - Intellectia AI
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-Than-Expected Loss Amid No RevenueAnalyst Earnings Estimate - newsline.com
Daily Brief Health Care: Parabilis Medicines, Integral Diagnostics, Healthequity Inc, ICON PLC, KT Medical Service, Leong Guan Holdings, Oramed Pharmaceuticals , Otsuka Holdings, Crism Therapeutics, TransCode Therapeutics and more - Smartkarma
Inside a new colorectal cancer trial: TransCode’s June 18 webcast with Harvard oncologist - Stock Titan
RNAZ: Introducing RNA Therapeutics - Yahoo Finance
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-Than-Expected Loss Amid Continued Pipeline DevelopmentMid-Term Outlook - newsline.com
RNAZ Q4 2024 Earnings: Wider-than-expected loss amid pre-revenue stageNet Profit Margin - newsline.com
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study - Sahm
Exclusive: TransCode's RNA therapeutic achieves 64% stable disease rate in colorectal cancer phase 1 study - MSN
TransCode Therapeutics (RNAZ) Advances to Phase 2a Following Pos - GuruFocus
RNAZ | TransCode Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
TransCode Therapeutics Advances TTX-MC138 After Positive Phase 1a - TipRanks
TransCode completes phase 1a trial of cancer drug TTX-MC138 By Investing.com - Investing.com Australia
TransCode Therapeutics (RNAZ) sees clean Phase 1a safety, 64% stable disease with TTX-MC138 - Stock Titan
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer - PR Newswire
TransCode Therapeutics (RNAZ) proxy bundles big equity, financing and director votes - Stock Titan
TransCode Therapeutics sets date for 2026 annual meeting and proposal deadlines - Investing.com Nigeria
TransCode Sets Key Deadlines for 2026 Shareholder Meeting - TipRanks
TransCode Therapeutics, Inc. Files Form 8-K with NASDAQ Listing and Company Details (RNAZ) - Minichart
TransCode Therapeutics sets date for 2026 annual meeting and proposal deadlines By Investing.com - Investing.com South Africa
TransCode Therapeutics (RNAZ) sets July 2, 2026 annual meeting and June 11 proposal cutoff - Stock Titan
(RNAZ) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
RNAZ Stock Price, Quote & Chart | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
TransCode Therapeutics Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease - citybuzz -
TransCode initiates phase 2a trial for colorectal cancer drug By Investing.com - Investing.com Australia
TransCode Therapeutics Initiates Phase 2a Clinical Trial With TTX-MC138 in Patients With CtDNA Positive Colorectal Cancer - Moomoo
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer - PR Newswire
TransCode Therapeutics (RNAZ) Drops 10.66%: Support at $5.3 Faces Critical Test After Sharp DeclineCTA Positioning - The Legal Advocate
RNAZTransCode Therapeutics Inc Stock Price and Quote - Finviz
TransCode Therapeutics Files 8-K/A Detailing Nasdaq Compliance Plan and Soliciting Material Disclosure - Minichart
Nasdaq warns TransCode (NASDAQ: RNAZ) on equity shortfall and delisting risk - Stock Titan
TransCode Therapeutics (RNAZ) Gains Over 2% as Biotech Stock Tests Key Resistance LevelsStop Hunt - newsline.com
TransCode Therapeutics Receives Nasdaq Listing Deficiency Notice - TipRanks
TransCode Therapeutics (RNAZ) Surges 2% as Biotech Stock Tests Key Resistance at $6.55Head and Shoulders - Newser
TransCode Therapeutics (NASDAQ: RNAZ) warned on Nasdaq equity shortfall - Stock Titan
1.47%
2.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):